Bayesian Capital Management, LP Biocryst Pharmaceuticals Inc Transaction History

Bayesian Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $178,416 - $293,328	43,200 New	43,200 $266,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $90,138 - $122,536	-18,100 Reduced 23.0%	60,600 $362,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $427,427 - $504,504	63,700 Added 424.67%	78,700 $557,000
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $104,400 - $132,150	15,000 New	15,000 $105,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $436,498 - $599,123	40,454 New	40,454 $510,000
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $51,490 - $152,031	-27,100 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $43,360 - $111,381	27,100 New	27,100 $54,000

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.